



## Clinical Study Synopsis for Public Disclosure

This clinical study synopsis is provided in line with **Boehringer Ingelheim's Policy on Transparency and Publication of Clinical Study Data**.

The synopsis - which is part of the clinical study report - had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion.

The synopsis may include approved and non-approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities.

A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country..

Additional information on this study and the drug concerned may be provided upon request based on **Boehringer Ingelheim's Policy on Transparency and Publication of Clinical Study Data**.

The synopsis is supplied for informational purposes only in the interests of scientific disclosure. It must not be used for any commercial purposes and must not be distributed, published, modified, reused, posted in any way, or used for any other purpose without the express written permission of Boehringer Ingelheim.

**Other Clinical Report**

<b>Document Number: c11684300-01</b>	
<b>BI Trail No.:</b>	1219.4
<b>EudraCT No.:</b>	2007-003742-15
<b>BI Investigational Product:</b>	BIBW 2948 BS inhalation powder, hard capsule for HandiHaler®
<b>Title:</b>	A phase II, randomised, double-blind, placebo-controlled and parallel group study to evaluate the safety and efficacy of four weeks treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) in patients with COPD associated with chronic bronchitis.
<b>Clinical Phase:</b>	II a
<b>GCP Compliance:</b>	Yes
<b>Authors:</b>	██████████ ██████████
<b>Principal/Coord. Investigator:</b>	██████████ ██████████
<b>Institute/ Department:</b>	██████████ ████████████████████ ██ ██
<b>Date of Report:</b>	29 Jul 2016
<b>Dates of Trial:</b>	From 15 Sep 2008                      From 16 Sep 2008
<b>Additional Reports:</b>	
<b>Page 1 of 5</b>	
<b>Proprietary confidential information</b> © 2016 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved. This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission	

---

Proprietary confidential information © 2016 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

**2. TABLE OF CONTENTS**

<b>1.</b>	<b>TITLE PAGE .....</b>	<b>1</b>
<b>2.</b>	<b>TABLE OF CONTENTS.....</b>	<b>2</b>
<b>3.</b>	<b>INTRODUCTION.....</b>	<b>3</b>
<b>4.</b>	<b>METHODOLOGY.....</b>	<b>5</b>
<b>5.</b>	<b>RESULTS .....</b>	<b>5</b>
<b>6.</b>	<b>DISCUSSION .....</b>	<b>5</b>
<b>7.</b>	<b>LITERATRURE REFERENCES .....</b>	<b>5</b>
<b>7.1</b>	<b>PUBLISHED REFERENCES.....</b>	<b>5</b>
<b>7.2</b>	<b>UNPUBLISHED REFERENCES.....</b>	<b>5</b>

### **3. INTRODUCTION**

Study results 1219.5 revealed compromising safety findings after unblinding the data for the active (BIBW2948 BS 30 mg b.i.d. and 15 mg b.i.d) vs. placebo groups. These findings comprise a significant decline in FEV1 after 4 weeks of treatment with BIBW 2948 BS at doses of 30 mg b.i.d. as well as 15 mg b.i.d., an increase in patient reported rescue medication use and cough, and an imbalance in treatment drop-outs for respiratory reasons.

In consequence it was decided to not expose further patients to doses of 15 mg b.i.d. BIBW 2948 BS or higher. Based on these results the just initiated study 1219.4 was halted.

#### **Trial Data**

FPI: 15 September 2008

LPO: 16 September 2008

Number of patient: 1 patient only enrolled and withdrew before randomisation.

#### **PRIMARY ENDPOINT**

The primary endpoint of this study will be change in CASA-Q symptom domain scores from baseline to the end of the 4-week treatment period.

#### **SECONDARY ENDPOINTS**

##### **1 Efficacy endpoints**

Secondary efficacy endpoints are the change from baseline in:

1. CASA-Q symptom domain scores
2. CASA-Q cough impact score
3. CASA-Q sputum impact score
4. 24-hour sputum wet weight
5. 24-hour sputum dry weight
6. 24-hour sputum volume
7. Cough frequency as recorded by the LifeShirt® device
8. Cough and Sputum Rating Scales
9. Patient and Physician reported impression of change (PGI-C and CGI-C)
10. Interleukin-8 (IL-8) plasma levels

##### **2 Safety endpoints**

1. Changes from baseline in lung function as measured by post-bronchodilator FEV<sub>1</sub>
2. Changes from baseline in lung function as measured by post-bronchodilator FVC
3. Safety clinical laboratory parameters

Haematology: haemoglobin, hematocrit, erythrocytes, platelets, total leukocyte count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), and absolute eosinophil count.

Biochemistry: albumin, alkaline phosphatase, calcium, chloride, creatinine, glucose, inorganic phosphorus, lactate dehydrogenase (LDH), potassium, gamma glutamyl transferase (GGT), carbohydrate deficient transferrin (CDT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), sodium, reflexive bilirubin (direct and indirect), total protein, uric acid and urea nitrogen.

4. Mean weekly morning peak expiratory flow (a.m. pre-dose measurement) as collected in the Patient Daily Diary.
5. Vital signs (PR, BP).
6. Reported adverse events.

### **3 Pharmacokinetics endpoints**

The following pharmacokinetic endpoints will be derived from drug plasma concentrations of the main metabolite BIBW 3056 ZW to evaluate exposure to BIBW 2948 BS/ BIBW 3056 ZW.

#### **3.1 Routine Pharmacokinetic Analyses for all patients**

- $C_{\max,ss}$  (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval  $\tau$ ).
- $t_{\max,ss}$  (time from last dosing to maximum concentration of the analyte in plasma at steady state).
- $C_{\text{pre},ss}$  (predose steady state concentration of the analyte immediately before administration of the next dose).

#### **3.2 Subgroup Pharmacokinetic Analyses for Selected Sites Only**

17 patients per treatment group with more frequent blood sampling will take part in 6-hour post-dose measurement of the main metabolite BIBW 3056 ZW to evaluate exposure to BIBW 2948 BS/ BIBW 3056 ZW:

$AUC_{0-6,ss}$  (area under the concentration-time curve of the analyte in plasma at steady state from 0 to 6 hours)

**4. METHODOLOGY**

N/A

**5. RESULTS**

N/A

**6. DISCUSSION**

1 subject was enrolled. The trial was terminated prior to randomization of subjects.

**7. LITERATURE REFERENCES**

**7.1 PUBLISHED REFERENCES**

None

**7.2 UNPUBLISHED REFERENCES**

None